Rheumatology.net

Rheumatology Xagena

Search results for "Apremilast"

Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of adult patients with active psoriatic arth ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis ( PsA ) in 2012, new evidence and new therapeutic age ...